A trusted leader dedicated to transforming the lives of people with immune-mediated diseases, today and tomorrow.
With each new discovery, we create a better understanding of how patients are different — even those diagnosed with the same disease — so we can develop more personalized approaches to immunological diseases. More than 1 million people with immune-mediated diseases worldwide are treated with our therapies.
We’re building on our deep expertise and historic legacy in immunology research to explore new disease areas, create a more patient-centric discovery and development process, and offer solutions for more diverse patient populations. Our advanced technologies support a rich pipeline of medicines for some of the most challenging immunological diseases. Research interests include:
Understanding drivers of disease
Increasing understanding of disease through molecular profiling of patient samples, exploring preclinical disease to post-treatment states and using multi-omics, machine learning and artificial intelligence.
Fit for purpose drug discovery
Redesigning drug discovery using molecular profiles that reveal the genetic makeup of disease rather than diagnoses that describe disease.
Increasing probability of success in drug discovery
Developing more humanized preclinical model systems (e.g., CRISPR, iPSC, organoids and disease-on-a-chip) and state-of-the-art immunological, imaging and computational approaches to drive innovation of target identification, validation, benchmarking and prioritization.
Inducing of immune tolerance
Pursuing the biology behind inducing tolerance rather than suppressing pathological immune activity.
Drug delivery platforms
Investing in targeted drug delivery platforms, which are designed to specifically deliver a potent drug to the right cells and/or tissues. These include bispecifics, Antibody-Drug Conjugate platforms, small molecule approaches, RNA therapeutics and in situ cell reprogramming.
We work to help people living with chronic, progressive diseases in rheumatology, dermatology and gastroenterology live full lives without limits from their disease.
Strategic collaborations bring together the brightest minds in immunology working to bring more options to patients, faster. We join forces with partners that complement our strengths, capabilities and commitment to people with immune-mediated diseases.
Innovation in this area helps researchers understand complex immune-mediated diseases, from how a person’s genetics affect disease to leveraging clinical trial data to deliver personalized medicine. Advanced technologies like molecular profiling and biomarker analyses allow us to dig even deeper.
We have nearly a quarter-century of experience in immune-mediated disease, and we’re not stopping. We continue to investigate diseases with critical unmet diseases, building robust development programs that advance how the disease is treated.
Help us create the future of medicine.
The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence. The Internet site that you have requested may not be optimized to your screen size. Do you wish to continue to this product-specific site?